JP2010511665A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511665A5
JP2010511665A5 JP2009539730A JP2009539730A JP2010511665A5 JP 2010511665 A5 JP2010511665 A5 JP 2010511665A5 JP 2009539730 A JP2009539730 A JP 2009539730A JP 2009539730 A JP2009539730 A JP 2009539730A JP 2010511665 A5 JP2010511665 A5 JP 2010511665A5
Authority
JP
Japan
Prior art keywords
formulation
rabies virus
antibody
temperature
chain seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009539730A
Other languages
English (en)
Japanese (ja)
Other versions
JP5410985B2 (ja
JP2010511665A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/063244 external-priority patent/WO2008068246A1/en
Publication of JP2010511665A publication Critical patent/JP2010511665A/ja
Publication of JP2010511665A5 publication Critical patent/JP2010511665A5/ja
Application granted granted Critical
Publication of JP5410985B2 publication Critical patent/JP5410985B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009539730A 2006-12-05 2007-12-04 液体抗狂犬病抗体製剤 Expired - Fee Related JP5410985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87289206P 2006-12-05 2006-12-05
EP06125400 2006-12-05
US60/872,892 2006-12-05
EP06125400.9 2006-12-05
PCT/EP2007/063244 WO2008068246A1 (en) 2006-12-05 2007-12-04 Liquid anti-rabies antibody formulations

Publications (3)

Publication Number Publication Date
JP2010511665A JP2010511665A (ja) 2010-04-15
JP2010511665A5 true JP2010511665A5 (enExample) 2011-01-20
JP5410985B2 JP5410985B2 (ja) 2014-02-05

Family

ID=39092188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539730A Expired - Fee Related JP5410985B2 (ja) 2006-12-05 2007-12-04 液体抗狂犬病抗体製剤

Country Status (13)

Country Link
US (1) US7959922B2 (enExample)
EP (1) EP2088997B1 (enExample)
JP (1) JP5410985B2 (enExample)
KR (1) KR101522036B1 (enExample)
CN (1) CN101557799B (enExample)
AU (1) AU2007328960B2 (enExample)
CA (1) CA2668947C (enExample)
CU (1) CU23795A3 (enExample)
EA (1) EA017549B1 (enExample)
IL (1) IL199004A (enExample)
MX (1) MX2009005414A (enExample)
WO (1) WO2008068246A1 (enExample)
ZA (1) ZA200902772B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
WO2005118644A2 (en) * 2004-05-27 2005-12-15 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
MX2009005414A (es) 2006-12-05 2009-06-01 Crucell Holland Bv Formulaciones liquidas de anticuerpo antirrabico.
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
MX362191B (es) * 2012-03-07 2019-01-08 Lilly Co Eli Formulacion de anticuerpo il-17.
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JP7159642B2 (ja) * 2018-06-26 2022-10-25 東ソー株式会社 カラムの抗体に対する保持力の測定方法
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合tnfr2的抗體及其用途
CN119405798A (zh) * 2022-04-02 2025-02-11 重庆智翔金泰生物制药股份有限公司 一种治疗狂犬病的抗体药物组合物及其制备方法
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062364T3 (es) 1989-06-08 1994-12-16 Wistar Inst Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
CA2457362C (en) 2001-08-21 2012-01-17 Thomas Jefferson University Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
WO2005023849A2 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
JP4671864B2 (ja) * 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 IgM高濃度安定化溶液
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
WO2005118644A2 (en) * 2004-05-27 2005-12-15 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
ES2407468T3 (es) * 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
MX2009005414A (es) 2006-12-05 2009-06-01 Crucell Holland Bv Formulaciones liquidas de anticuerpo antirrabico.

Similar Documents

Publication Publication Date Title
CN110062620B (zh) 液体药物组合物
EP3681483B1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
JP5410985B2 (ja) 液体抗狂犬病抗体製剤
JP7695277B2 (ja) 安定なペプチド組成物
JP2000504327A (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子▲ix▼処方
RS66182B1 (sr) Stabilne višedozne kompozicije koje sadrže antitelo i konzervans
RU2484847C2 (ru) Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения
AU6757600A (en) Rotavirus vaccine formulations
JP4871720B2 (ja) 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
CN107645956B (zh) 包含阿那白滞素的组合物
JP7798791B2 (ja) ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用
WO2025005804A1 (en) Mucoadhesive formulation
JP2023525565A5 (enExample)
EP4734957A1 (en) Mucoadhesive formulation
JP2024543931A5 (enExample)
AU2008202660B2 (en) Rotavirus vaccine formulations
JP2023501155A5 (enExample)
JP2023553641A (ja) 抗il5r抗体製剤
EA043419B1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
HK40033832B (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
CN1897929A (zh) 包含5-甲基-2-(2′-氯-6′-氟苯胺基)苯乙酸的药物组合物
NZ739899B2 (en) Biopharmaceutical compositions